XML 62 R10.htm IDEA: XBRL DOCUMENT
v3.26.1

Loss per share | 6 Months Ended
--- | ---
Jun. 30, 2026
Loss per share |
Loss per share | 4.Loss per share ​
​ | ​ | ​ | ​ | ​
​ | ​ | For the Six Months
​ | ​ | Ended June 30,
In CHF thousands except for share and per share data | ​ ​ ​ | 2026 | ​ | 2025
Loss per share (EPS) | ​ | ​ | ​ ​ ​ | ​
Numerator | ​ | ​ |  | ​
Net loss attributable to equity holders of the Company | ​ | (12,927) |  | (40,218)
Denominator | ​ | ​ |  | ​
Weighted-average number of shares outstanding used to compute EPS basic and diluted attributable to equity holders | ​ | 101,963,177 |  | 100,519,884
Basic and diluted loss per share for the period attributable to equity holders | ​ | (0.13) |  | (0.40)
​ In periods for which AC Immune has a loss, basic net loss per share is the same as diluted net loss per share. The Company has excluded from the calculation of diluted loss per share all potentially dilutive in-the-money share options. See “Note 12. Share-based compensation” for the potentially dilutive equity awards.

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 33 -IssueDate 2025-01-01 -Section Disclosure -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI -URIDate 2025-03-27 + Details
Name: | ifrs-full_DisclosureOfEarningsPerShareExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_EarningsPerShareAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration